Équipe
Etienne Chatelut
DIAD :
Individualisation des doses de médicaments anticancéreux
Les spécificités
de notre axe de recherche
Pharmacocinétique
Pharmacogénétique
Individualisation des traitements
Suivi thérapeutique pharmacologique
Chromatographie liquide
Molécules radiomarquées théranostiques
Prédisposition génétique familiale
DES PROJETS
DE RECHERCHE
Thérapies orales : Adaptation des posologies d’anticancéreux oraux chez les patients ne pouvant pas avaler.
Dr Cécile Arellano & Dr Florent Puisset
Projets MATADOR et EXPECT : identification de nouveaux facteurs prédictifs du cancer du sein chez l’homme (MATADOR) et du cancer du colon jeune (EXPECT).
Dr Christine Toulas
Modélisation pharmacocinétique d’anticorps radiomarqués pour comprendre les mécanismes de résistance en immunothérapie
Dr Mélanie White-Koning
Quantifier les sources de variabilité interindividuelle de l’exposition à l’hormonothérapie
Dr Fabienne Thomas
Pharmacocinétique et molécules radiomarquées théranostiques
Dr Lawrence Dierickx
Pharmacocinétique et thérapeutiques innovantes
Dr Ben Allal
LES FOCUS
DE L’ÉQUIPE
Découvrir
Comprendre
Participer
PRODUCTIONS SCIENTIFIQUES
PUBLICATIONS 2023
Boumaza, Xavier, Margaux Lafaurie, Emmanuel Treiner, Ondine Walter, Gregory Pugnet, Guillaume Martin-Blondel, Damien Biotti, et al. “Infectious Risk When Prescribing Rituximab in Patients with Hypogammaglobulinemia Acquired in the Setting of Autoimmune Diseases.” International Immunopharmacology 120 (July 2023): 110342. https://doi.org/10.1016/j.intimp.2023.110342.
Valentin, Thibaud, Marie Lambert, Léonor Chaltiel, Ben Allal, Mourad Mseddi, Malika Yakoubi, Christine Chevreau, et al. “Population Pharmacokinetic Analysis Reveals No Impact of Aprepitant on the Pharmacokinetics of Ifosfamide, 2-Dechloroifosfamide, and 3-Dechloroifosfamide.” European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 185 (June 1, 2023): 106420. https://doi.org/10.1016/j.ejps.2023.106420.
Royer, B., M. Launay, J. Ciccolini, L. Derain, F. Parant, F. Thomas, and J. Guitton. “Impact of Renal Impairment on Dihydropyrimidine Dehydrogenase (DPD) Phenotyping.” ESMO Open 8, no. 3 (June 2023): 101577. https://doi.org/10.1016/j.esmoop.2023.101577.
Jong, Loek A. W. de, Marie Lambert, Nielka P. van Erp, Lukas de Vries, Etienne Chatelut, and Petronella B. Ottevanger. “Systemic Exposure to Cisplatin and Paclitaxel after Intraperitoneal Chemotherapy in Ovarian Cancer.” Cancer Chemotherapy and Pharmacology, March 9, 2023. https://doi.org/10.1007/s00280-023-04512-z.
Laloi, Louise, Natacha Chaumard Billotey, Pierre-Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, et al. “Retrospective, Real-Life Study of Venetoclax plus Azacitidine or Low-Dose Cytarabine in French Patients with Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy.” Cancer Medicine 12, no. 6 (March 2023): 7175–81. https://doi.org/10.1002/cam4.5459.
Poumeaud, François, Florence Dalenc, Quentin Mathevet, Aurélie Brice, Audrey Eche-Gass, Eleonora De Maio D’Esposito, Clémence Brac-de-la-Perriere, and Fabienne Thomas. “Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.” JCO Precision Oncology 7 (March 2023): e2200508. https://doi.org/10.1200/PO.22.00508.
Puisset, Florent, Félicien Le Louedec, Florence Dalenc, Lorène Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, et al. “Investigating the Clinical Impact of Dose-Banding for Weekly Paclitaxel in Patients with Breast Cancer: A Retrospective and Monocentric Study.” British Journal of Clinical Pharmacology, February 28, 2023. https://doi.org/10.1111/bcp.15702.
Overbeek, J. K., R. Ter Heine, H. M. W. Verheul, E. Chatelut, M. A. Rudek, H. Gurney, R. Plummer, et al. “Off-Label, but on Target: The Evidence Needed to Implement Alternative Dosing Regimens of Anticancer Drugs.” ESMO Open 8, no. 1 (February 2023): 100749. https://doi.org/10.1016/j.esmoop.2022.100749.
Maillard, Maud, Manon Launay, Bernard Royer, Jérôme Guitton, Elodie Gautier-Veyret, Sophie Broutin, Camille Tron, et al. “Quantitative Impact of Pre-Analytical Process on Plasma Uracil When Testing for Dihydropyrimidine Dehydrogenase Deficiency.” British Journal of Clinical Pharmacology 89, no. 2 (February 2023): 762–72. https://doi.org/10.1111/bcp.15536.
Puisset, Florent, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Etienne Chatelut, and Christine Chevreau. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.” Cancers 15, no. 1 (January 3, 2023): 313. https://doi.org/10.3390/cancers15010313.
Le Louedec, Félicien, Florent Puisset, Etienne Chatelut, and Michel Tod. “Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.” Clinical Pharmacokinetics 62, no. 1 (January 2023): 55–66. https://doi.org/10.1007/s40262-022-01200-8.
PUBLICATIONS 2022
Etienne-Grimaldi, Marie-Christine, Nicolas Pallet, Valérie Boige, Joseph Ciccolini, Laurent Chouchana, Chantal Barin-Le Guellec, Aziz Zaanan, et al. “Current Diagnostic and Clinical Issues of Screening for Dihydropyrimidine Dehydrogenase Deficiency.” European Journal of Cancer (Oxford, England: 1990) 181 (December 9, 2022): 3–17. https://doi.org/10.1016/j.ejca.2022.11.028.
Thomas, Fabienne, Manon Launay, Jérôme Guitton, Marie-Anne Loriot, Jean-Christophe Boyer, Vincent Haufroid, Marie-Christine Etienne-Grimaldi, Bernard Royer, and GPCO-UNICANCER Group. “Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!” Clinical Pharmacology and Therapeutics, November 22, 2022. https://doi.org/10.1002/cpt.2772.
Maillard, Maud, Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas J. Cabaton, Frédéric Pont, Nathalie Saint-Laurent, Thierry Lafont, Etienne Chatelut, and Fabienne Thomas. “Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury.” Metabolites 12, no. 9 (September 11, 2022): 852. https://doi.org/10.3390/metabo12090852.
Jong, Loek A. W. de, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, et al. “Correction to: Wide Variation in Tissue, Systemic, and Drain Fluid Exposure after Oxaliplatin‑based HIPEC: Results of the GUTOX Study.” Cancer Chemotherapy and Pharmacology, June 22, 2022. https://doi.org/10.1007/s00280-022-04450-2.
Maillard, Maud, Baptiste Louveau, Paul Vilquin, Lauriane Goldwirt, Fabienne Thomas, and Samia Mourah. “Pharmacogenomics in Solid Cancers and Hematologic Malignancies: Improving Personalized Drug Prescription.” Therapie 77, no. 2 (April 2022): 171–83. https://doi.org/10.1016/j.therap.2021.11.003.
Krache, Anis, Charlotte Fontan, Carine Pestourie, Manuel Bardiès, Yann Bouvet, Pierre Payoux, Etienne Chatelut, Melanie White-Koning, and Anne-Sophie Salabert. “Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.” Frontiers in Medicine 8 (January 31, 2022): 741855. https://doi.org/10.3389/fmed.2021.741855.
Grand, Anaïs, Jean-Baptiste Desbouges, Coralie Guillemot, Coline Spinau, and Florent Puisset. “Still Some Constraints Before Generalization of Remote Clinical Trial Monitoring: A Pharmacist’s Point of View of the Lessons From the COVID-19 Pandemic.” JCO Oncology Practice, January 6, 2022, OP2100749. https://doi.org/10.1200/OP.21.00749.
Lambert, Marie, Lawrence Dierickx, Séverine Brillouet, Frédéric Courbon, and Etienne Chatelut. “Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors.” Current Radiopharmaceuticals 15, no. 2 (2022): 164–72. https://doi.org/10.2174/1874471015666211228123525.
PUBLICATIONS 2021
Malier, Marie, Khaldoun Gharzeddine, Marie-Hélène Laverriere, Sabrina Marsili, Fabienne Thomas, Thomas Decaens, Gael Roth, and Arnaud Millet. “Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.” Cancer Research 81, no. 23 (December 1, 2021): 5963–76. https://doi.org/10.1158/0008-5472.CAN-21-1572.
Clarke, William A., Etienne Chatelut, Alan K. Fotoohi, Richard A. Larson, Jennifer H. Martin, Ron H. J. Mathijssen, and Salvatore J. Salamone. “Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Consensus Guidelines for Imatinib Therapy.” European Journal of Cancer (Oxford, England: 1990) 157 (November 2021): 428–40. https://doi.org/10.1016/j.ejca.2021.08.033.
Le Louedec, Félicien, Florent Puisset, Fabienne Thomas, Étienne Chatelut, and Mélanie White-Koning. “Easy and Reliable Maximum a Posteriori Bayesian Estimation of Pharmacokinetic Parameters with the Open-Source R Package Mapbayr.” CPT: Pharmacometrics & Systems Pharmacology 10, no. 10 (October 2021): 1208–20. https://doi.org/10.1002/psp4.12689.
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Lucie Obéric, Ben Allal, Etienne Chatelut, and Mélanie White-Koning. “Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.” Clinical Pharmacology and Therapeutics 110, no. 1 (July 2021): 220–28. https://doi.org/10.1002/cpt.2189.
White-Koning, Melanie, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, and Florent Puisset. “Correction to: Formulae Recently Proposed to Estimate Renal Glomerular Filtration Rate Improve the Prediction of Carboplatin Clearance.” Cancer Chemotherapy and Pharmacology 88, no. 1 (July 2021): 171. https://doi.org/10.1007/s00280-021-04268-4.
Thomas, F., M. Maillard, M. Launay, C. Tron, M.-C. Etienne-Grimaldi, E. Gautier-Veyret, V. Haufroid, et al. “Artificial Increase of Uracilemia during Fluoropyrimidine Treatment Can Lead to DPD Deficiency Misinterpretation.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 32, no. 6 (June 2021): 810–11. https://doi.org/10.1016/j.annonc.2021.02.020.
Mourey, Loïc, Félicien Le Louedec, Alain Ravaud, Marie-Noëlle Paludetto, Laurence Digue, Carlos Alberto Gomez-Roca, Thibaud Valentin, et al. “VOTRAGE Study: Phase I Dose-Escalation Study of Pazopanib in Unfit Older Patients.” Journal of Geriatric Oncology 12, no. 5 (June 2021): 759–64. https://doi.org/10.1016/j.jgo.2021.02.006.
Puszkiel, Alicja, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, et al. “Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.” Clinical Pharmacology and Therapeutics 109, no. 5 (May 2021): 1244–55. https://doi.org/10.1002/cpt.2077.
Maillard, Maud, Audrey Eche-Gass, Mony Ung, Aurélie Brice, Sabrina Marsili, Marion Montastruc, Florent Puisset, and Fabienne Thomas. “Severe Toxicity of Capecitabine in a Patient with DPD Deficiency after a Safe FEC-100 Experience: Why We Should Test DPD Deficiency in All Patients before High-Dose Fluoropyrimidines.” Cancer Chemotherapy and Pharmacology 87, no. 4 (April 2021): 579–83. https://doi.org/10.1007/s00280-021-04233-1.
Chevreau, Christine, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean-Pierre Lotz, Jacques-Olivier Bay, et al. “Multicentric Phase II Trial of TI-CE High-Dose Chemotherapy with Therapeutic Drug Monitoring of Carboplatin in Patients with Relapsed Advanced Germ Cell Tumors.” Cancer Medicine 10, no. 7 (April 2021): 2250–58. https://doi.org/10.1002/cam4.3687.
Medrano, Chloé, Lucie Oberic, Florent Puisset, Christian Recher, Delphine Larrieu-Ciron, Loïc Ysebaert, Caroline Protin, et al. “Life-Threatening Complications after High-Dose Methotrexate and the Benefits of Glucarpidase as Salvage Therapy: A Cohort Study of 468 Patients.” Leukemia & Lymphoma 62, no. 4 (April 2021): 846–53. https://doi.org/10.1080/10428194.2020.1846733.
Chatelut, Etienne, Jeroen J. M. A. Hendrikx, Jennifer Martin, Joseph Ciccolini, and Dirk Jan A. R. Moes. “Unraveling the Complexity of Therapeutic Drug Monitoring for Monoclonal Antibody Therapies to Individualize Dose in Oncology.” Pharmacology Research & Perspectives 9, no. 2 (April 2021): e00757. https://doi.org/10.1002/prp2.757.
Le Louedec, Félicien, Fanny Gallais, Fabienne Thomas, Mélanie White-Koning, Ben Allal, Caroline Protin, Loïc Ysebaert, Étienne Chatelut, and Florent Puisset. “Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data.” Pharmaceuticals (Basel, Switzerland) 14, no. 2 (February 18, 2021). https://doi.org/10.3390/ph14020162.
Larroque-Lombard, Anne-Laure, Etienne Chatelut, Jean-Pierre Delord, Diane-Charlotte Imbs, Philippe Rochaix, Bertrand Jean-Claude, and Ben Allal. “Design and Mechanism of Action of a New Prototype of Combi-Molecule ‘Programed’ to Release Bioactive Species at a PH Range Akin to That of the Tumor Microenvironment.” Pharmaceuticals (Basel, Switzerland) 14, no. 2 (February 16, 2021). https://doi.org/10.3390/ph14020160.
PUBLICATIONS 2020
Maillard, Maud, Christine Chevreau, Félicien Le Louedec, Manon Cassou, Caroline Delmas, Laure Gourdain, Jean-Yves Blay, et al. “Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.” Cancers 12, no. 12 (December 4, 2020): 3647. https://doi.org/10.3390/cancers12123647.
Le Louedec, Félicien, Fanny Leenhardt, Clémence Marin, Étienne Chatelut, Alexandre Evrard, and Joseph Ciccolini. “Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective.” Vaccines 8, no. 4 (October 31, 2020): 632. https://doi.org/10.3390/vaccines8040632.
Lambert, Marie, Melanie White‐Koning, Mathieu Alonso, Arnaud Garnier, Gwennaelle Alphonsa, Chloé Puiseux, Caroline Munzer, et al. “Plasma Cystatin C Is a Marker of Renal Glomerular Injury in Children Treated with Cisplatin or Ifosfamide.” Pediatric Blood & Cancer, October 15, 2020. https://doi.org/10.1002/pbc.28747.
Le Louedec, Félicien, and Etienne Chatelut. “Correlation between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality. Letter to the Editor.” The Oncologist, October 12, 2020, onco.13564. https://doi.org/10.1002/onco.13564.
Maillard, Maud, Félicien Le Louedec, Fabienne Thomas, and Etienne Chatelut. “Diversity of Dose-Individualization and Therapeutic Drug Monitoring Practices of Platinum Compounds: A Review.” Expert Opinion on Drug Metabolism & Toxicology, October 5, 2020, 1–19. https://doi.org/10.1080/17425255.2020.1789590.
Gallais, Fanny, Lucie Oberic, Stanislas Faguer, Suzanne Tavitian, Thierry Lafont, Sabrina Marsili, Aurélie Brice, Etienne Chatelut, and Florent Puisset. “Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.” Therapeutic Drug Monitoring Publish Ahead of Print (September 10, 2020). https://doi.org/10.1097/FTD.0000000000000813.
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, et al. “Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.” Clinical Pharmacokinetics 59, no. 9 (September 2020): 1171–83. https://doi.org/10.1007/s40262-020-00884-0.
White-Koning, Melanie, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, and Florent Puisset. “Formulae Recently Proposed to Estimate Renal Glomerular Filtration Rate Improve the Prediction of Carboplatin Clearance.” Cancer Chemotherapy and Pharmacology, January 9, 2020. https://doi.org/10.1007/s00280-019-04020-z.
Metsu, David, Thomas Lanot, François Fraissinet, Didier Concordet, Véronique Gayrard, Manon Averseng, Alice Ressault, et al. “Comparing Ultrafiltration and Equilibrium Dialysis to Measure Unbound Plasma Dolutegravir Concentrations Based on a Design of Experiment Approach.” Scientific Reports 10, no. 1 (2020): 12265. https://doi.org/10.1038/s41598-020-69102-y.
Jong, Loek A. W. de, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, et al. “Wide Variation in Tissue, Systemic, and Drain Fluid Exposure after Oxaliplatin-Based HIPEC: Results of the GUTOX Study.” Cancer Chemotherapy and Pharmacology 86, no. 1 (2020): 141–50. https://doi.org/10.1007/s00280-020-04107-y.
Moeung, Sotheara, Christine Chevreau, Sabrina Marsili, Christophe Massart, Aude Fléchon, Rémy Delva, Gwenaëlle Gravis, et al. “Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.” Pharmaceutical Research 37, no. 7 (2020): 147. https://doi.org/10.1007/s11095-020-02861-5.
Chatelut, Etienne, Félicien Le Louedec, and Gérard Milano. “Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.” Clinical Pharmacokinetics 59, no. 3 (2020): 287–96. https://doi.org/10.1007/s40262-019-00837-2.
PUBLICATIONS 2019
Paludetto, Marie-Noëlle, Jean-Luc Stigliani, Anne Robert, Vania Bernardes-Génisson, Etienne Chatelut, Florent Puisset, and Cécile Arellano. “Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples.” Chemical Research in Toxicology, September 26, 2019. https://doi.org/10.1021/acs.chemrestox.9b00205.
Soulès, Régis, Fabien Audouard-Combe, Emilie Huc-Claustre, Philippe de Medina, Arnaud Rives, Etienne Chatelut, Florence Dalenc, et al. “A Fast UPLC-HILIC Method for an Accurate Quantification of Dendrogenin A in Human Tissues.” The Journal of Steroid Biochemistry and Molecular Biology 194 (August 12, 2019): 105447. https://doi.org/10.1016/j.jsbmb.2019.105447.
Paludetto, Marie-Noëlle, Florent Puisset, Etienne Chatelut, and Cécile Arellano. “Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitors in a Comprehensive Approach: Implications for Drug-Drug Interactions and Hepatotoxicity.” Medicinal Research Reviews, May 20, 2019. https://doi.org/10.1002/med.21577.
Puszkiel, Alicja, Gaëlle Noé, Audrey Bellesoeur, Nora Kramkimel, Marie-Noëlle Paludetto, Audrey Thomas-Schoemann, Michel Vidal, François Goldwasser, Etienne Chatelut, and Benoit Blanchet. “Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.” Clinical Pharmacokinetics 58, no. 4 (April 2019): 451–67. https://doi.org/10.1007/s40262-018-0703-0.
Spinau, Coline, Florent Puisset, and Etienne Chatelut. “Carboplatine versus cisplatine - Pharmacocinétique, cytotoxicité, indications thérapeutiques.” ONKO+ 11, no. 85 (March 2019): 43–52.
Le Louedec, Félicien, Catherine Alix-Panabières, Thierry Lafont, Ben C. Allal, Renaud Garrel, Laurence Digue, Joël Guigay, et al. “Cetuximab Pharmacokinetic/Pharmacodynamics Relationships in Advanced Head and Neck Carcinoma Patients.” British Journal of Clinical Pharmacology, February 27, 2019. https://doi.org/10.1111/bcp.13907.
Puszkiel, Alicja, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, et al. “Factors Affecting Tamoxifen Metabolism in Breast Cancer Patients; Preliminary Results of the French PHACS Study (NCT01127295).” Clinical Pharmacology and Therapeutics, February 20, 2019. https://doi.org/10.1002/cpt.1404.
Puszkiel, Alicja, Mathilde Bauriaud-Mallet, Roxane Bourgeois, Lawrence Dierickx, Frédéric Courbon, and Etienne Chatelut. “Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.” Clinical Pharmacokinetics 58, no. 2 (February 2019): 213–22. https://doi.org/10.1007/s40262-018-0674-1.
Veal, Gareth J., Edward B. Amankwatia, Marie-Noëlle Paludetto, Till Möcklinghoff, Fiona Thomson, Nicolas André, Joseph Ciccolini, and Etienne Chatelut. “Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.” Therapeutic Drug Monitoring 41, no. 2 (2019): 142–59. https://doi.org/10.1097/FTD.0000000000000606.
Moeung, Sotheara, Christine Chevreau, Vianney Poinsignon, Jérôme Guitton, Bénédicte Lelièvre, Joseph Ciccolini, Laurence Gladieff, et al. “Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.” Therapeutic Drug Monitoring 41, no. 1 (2019): 66–74. https://doi.org/10.1097/FTD.0000000000000569.
LES MEMBRES DE L’ÉQUIPE
LES PARTENAIRES & FINANCIERS
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
2, avenue Hubert Curien
31037 - Toulouse - FR
CRCT-Oncopole Follow 1,220 1,117
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
;
Castelnau-Montratier célèbre la lutte contre le cancer. Jeudi 24 août 2023 conférence avec Frédéric Chibon responsable de l'équipe @OncoSarc du @crctoncopole accompagné de Gwenaël Ferron et Martin Gauthier oncologue @IUCTOncopole
Découvrir l'équipe
➡️https://www.crct-inserm.fr/oncosarc/
Nous contacter
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?
